HAMBURG, Germany, March 1, 2010 (GLOBE NEWSWIRE) -- Evotec AG (Frankfurt:EVT) (TecDAX) is going to broadcast its press & analyst conference in Frankfurt live on the internet. The Management Board of Evotec AG will inform you about the FY 2009 results as well as the status of the Discovery Alliance Business and the Company's development projects. Moreover, they will provide an update on the "Evotec 2012 -- Action Plan to Focus and Grow" and the business outlook for 2010. The conference will be held in English.
Date: Thursday, 25 March 2010
Time: 10.00 am CET (09.00 am GMT/05.00 am EDT)
To join the audio webcast and to access the presentation slides you will find a link on our home page www.evotec.com shortly before the event.
For those who prefer to listen to the presentation via phone, please dial:
From Europe: +49.(0)69.2222 7111 (Germany)
+44.(0)20.7784 1036 (UK)
From the US: +1.718.354 1358
Access Code: 9745589
Presentation: www.equitystory.com
Access code: evotec0310
The on-demand version of the webcast will be available on our website: www.evotec.com - Investors – Events - Financial Calendar.
About Evotec AG
Evotec is a leader in the discovery and development of novel small molecule drugs with operational sites in Europe and Asia. The Company has built substantial drug discovery expertise and an industrialized platform that can drive new innovative small molecule compounds into the clinic. In addition, Evotec has built a deep internal knowledge base in the treatment of diseases related to neuroscience, pain, and inflammation. Leveraging these skills and expertise, the Company intends to develop best-in-class differentiated therapeutics and deliver superior science-driven discovery alliances with pharmaceutical and biotechnology companies. Evotec has long-term discovery alliances with partners including Boehringer Ingelheim, CHDI, Novartis, Ono Pharmaceutical and Roche. Evotec has product candidates in clinical development and a series of preclinical compounds and development partnerships, including, for example, a strategic alliance with Roche for the EVT 100 compound family, subtype selective NMDA receptor antagonists for use in treatment-resistant depression. For additional information, please go to www.evotec.com.